January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 22, 2015

Camber Pharmaceuticals on Thursday announced the launch of pantoprazole sodium delayed-release tablets USP, the generic version of Pfizer's Protonix. The drug is used to treat gastro esophageal reflux disease and damage to the esophagus.

 

January 15, 2015

Mylan on Thursday announced the launch of lamivudine tablets, 100 mg, the generic version of Epivir-HBV from GlaxoSmithKline. 

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

January 13, 2015

Prasco Labs., Takeda Pharmacuetical Company Limited and Takeda's wholly owned subsidiary Takeda Pharmaceuticals U.S.A. on Tuesday announced that Prasco and TPUSA entered into a distribution and supply agreement for the rights to distribute colchicine tablets, USP, the authorized generic of Colcrys tablets. 

 

January 12, 2015

Perrigo on Monday announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex spray, 0.05%. 

January 9, 2015

Camber Pharmaceuticals on Friday announced the launch of zolmitriptan tablets in 2.5- and 5-mg dosage strengths.

January 8, 2015

Camber Pharmaceuticals on Thursday announced the launch of valsartan tablets USP in 40-, 80-, 106- and 320-mg dosage strengths.

 

January 7, 2015

Lupin Pharmaceuticals on Tuesday launched its valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. The drug is the generic version Novartis's Diovan tablets.

January 7, 2015

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

January 6, 2015

Aurobindo Pharma on Tuesday announced that the company has received final approval from the U.S. Food & Drug Administration to manufacture and market Valsartan Tablets.

January 5, 2015

Mylan announced the introduction of valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. 

December 22, 2014

The Food and Drug Administration granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.

December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.

December 16, 2014

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength. 

 

December 11, 2014

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate. 

December 9, 2014

From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period. 

December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. 

December 8, 2014

The pros of giving healthy women regular low dose aspirin to stave off such serious illness as cancer and heart disease are outweighed by the cons, suggests a large study published online last week in the journal Heart.

December 4, 2014

Camber Pharmaceuticals announced the addition of montelukast sodium tablets to its portfolio of products.

December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.

December 1, 2014

NACDS advocated for the voluntary ability of pharmacies to extend their reward and loyalty programs to beneficiaries in government programs.

December 1, 2014

Teva Pharmaceutical on Monday announced the launch of a generic version of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the United States. 

November 24, 2014

Dr. Reddy's Labs on Monday announced the launch of docetaxel injection USP in 20-mg and 80-mg dosage strengths. The drug is the generic version of Taxotere.